MX2022001186A - Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo. - Google Patents

Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo.

Info

Publication number
MX2022001186A
MX2022001186A MX2022001186A MX2022001186A MX2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A MX 2022001186 A MX2022001186 A MX 2022001186A
Authority
MX
Mexico
Prior art keywords
nitenin
treatment
sup
sub
compounds
Prior art date
Application number
MX2022001186A
Other languages
English (en)
Spanish (es)
Inventor
Santos Baltazar De Lima Pedro Afonso Dos
Dos Santos Beatriz Szwarc
Abreu Ana Rosa Maço
Bastos André Emanuel Pinheiro
Rui Gomes
De Sousa Marisa Isabel Lopes
Serrão Joana Maria Monteiro
Lino Sílvia Patrícia Pena
Silveira Máximo Patrícia Isabel Da
Ferreira Luísa Maria Pinto
Sério Branco Paula Cristina De
Mourão Henrique Sovela
Sabino Vanessa Alexandra Rosado
Tong Ming Him
Laurent Alain Claudetrembleau
Da Costa Lourenço Ana Maria Ferreira
Mondragão Miguel Angelo Segão
Original Assignee
Sea4Us Biotecnologia E Recursos Marinhos Lda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea4Us Biotecnologia E Recursos Marinhos Lda filed Critical Sea4Us Biotecnologia E Recursos Marinhos Lda
Publication of MX2022001186A publication Critical patent/MX2022001186A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/28Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/36Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2022001186A 2019-07-31 2020-07-22 Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo. MX2022001186A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT11568519 2019-07-31
PCT/IB2020/056915 WO2021019373A1 (en) 2019-07-31 2020-07-22 Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Publications (1)

Publication Number Publication Date
MX2022001186A true MX2022001186A (es) 2022-05-11

Family

ID=72240450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001186A MX2022001186A (es) 2019-07-31 2020-07-22 Compuestos analogos de nitenina y su uso en el tratamiento de dolor cronico y agudo.

Country Status (10)

Country Link
US (1) US12336977B2 (https=)
EP (1) EP4003984A1 (https=)
JP (1) JP2022544057A (https=)
CN (1) CN114616230A (https=)
AU (1) AU2020320115A1 (https=)
CA (1) CA3149175A1 (https=)
IL (1) IL290192A (https=)
MX (1) MX2022001186A (https=)
WO (1) WO2021019373A1 (https=)
ZA (1) ZA202201154B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4003984A1 (en) 2019-07-31 2022-06-01 Sea4Us - Biotecnologia e Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain
CN116115739B (zh) * 2022-12-29 2024-01-09 天津市肿瘤医院(天津医科大学肿瘤医院) 胃动素及其受体激动剂的应用
WO2026013449A2 (en) * 2024-07-11 2026-01-15 Sea4Us - Biotecnologia E Recursos Marinhos, Sa Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7375136B2 (en) 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
WO2007009462A2 (en) 2005-07-15 2007-01-25 Region Hovedstaden V/Glostrup Hospital Treatment of migraine and headaches
ES2345527B1 (es) 2008-10-08 2011-09-08 Hospital Clinic I Provincial De Barcelona Sustancias bloqueadoras de los canales kv 1.3 para el tratamiento de enfermedades asociadas a hiperplasia de la intima.
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 age-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
CN106537149A (zh) * 2014-04-01 2017-03-22 宝洁公司 用于筛选色氨酸通道的方法
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
CN106146530A (zh) * 2015-04-14 2016-11-23 中国科学院生态环境研究中心 一种合成cephalosporolides E,F,H,I的新方法
EP4003984A1 (en) 2019-07-31 2022-06-01 Sea4Us - Biotecnologia e Recursos Marinhos, Lda. Nitenin analogue compounds and their use in the treatment of chronic and acute pain

Also Published As

Publication number Publication date
CA3149175A1 (en) 2021-02-04
ZA202201154B (en) 2024-02-28
IL290192A (en) 2022-03-01
CN114616230A (zh) 2022-06-10
AU2020320115A1 (en) 2022-02-24
WO2021019373A4 (en) 2021-03-25
US12336977B2 (en) 2025-06-24
JP2022544057A (ja) 2022-10-17
WO2021019373A1 (en) 2021-02-04
EP4003984A1 (en) 2022-06-01
US20220288017A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
ZA202201154B (en) Nitenin analogue compounds and their use in the treatment of chronic and acute pain
GEP20237568B (en) 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
PH12021551300A1 (en) Synergistic compositions of bioactive agents for optimizing cellular health
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
WO2018106108A8 (en) Topical pharmaceutical composition containing phenytoin and a (co -)an algesic for the treatment of chronic pain
ZA202000028B (en) Use of vibegron to treat overactive bladder
WO2009129527A3 (en) Baclofen formulation in a polyorthoester carrier
PH12021550965A1 (en) Combination therapy for treatment of hematological diseases
MX2023007080A (es) Metodo para el tratamiento de la fibrosis.
PH12022550843A1 (en) Thienopyrimidones as trpa1 inhibitors
MX2021005967A (es) Formas purificadas de rofecoxib, métodos de fabricación y uso.
SA519410993B1 (ar) النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية
MX2024004319A (es) Extracto de ca?amo para el tratamiento de dolor, cancer y epilepsia en animales.
PH12022550846A1 (en) Thienopyrimidones as trpa1 inhibitors
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
CA3156680A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
GEAP202215466A (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
MX2022005448A (es) Método de tratamiento de queratodermia palmoplantar.
MX2023002416A (es) Compuestos, composiciones y metodos para la inhibicion de la desmetilasa de histona lisina.
PH12022552645A1 (en) Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2026013449A3 (en) Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain